← Back to 5-MeO-DiPT

5-MeO-DiPT Stats & Data

Foxy Foxy methoxy foxy-methoxy 5meodipt

PubChem CID 151182

PubChem

MW274.4

FormulaC17H26N2O

LogP3.1

IUPACN-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propan-2-ylpropan-2-amine

InChIKeyDNBPMBJFRRVTSJ-UHFFFAOYSA-N

Chemical Class Tryptamine

Psychoactive Class Psychedelic / Stimulant

Pharmacology

DrugBank

State Solid

Description

5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) is a tryptamine derivative and shares many similarities with schedule I tryptamine hallucinogens such as alpha-ethyltryptamine, N,N-dimethyltryptamine, N,N-diethyltryptamine, bufotenine, psilocybin and psilocin. Since 1999, there has been a growing popularity of 5-MeO-DIPT among drug abusers. This substance is abused for its hallucinogenic effects.

Pharmacodynamics

5-methoxy-diisopropyltryptamine, also known as 5-methoxy-N,N-diisopropyltryptamine, 5-MeO-DiPT, foxy methoxy, or just foxy, is a tryptamine that is used recreationally as a psychedelic. 5-MeO-DiPT is orally active, and dosages between 6–20 mg are commonly reported. Many users note an unpleasant body load accompanies higher dosages. 5-MeO-DiPT is also taken by insufflation, or sometimes it is smoked or injected. Some users also report sound distortion, also noted with the related drug, DiPT.

Absorption

5-MeO-DIPT produces effects with an onset of 20 to 30 minutes and with peak effects occurring between 1 to 1.5 hours after administration.

Receptor Profile

Receptor Actions

Agonists

5-HT2A receptor agonist (partial)

5-HT1A receptor agonist (strongest binding affinity)

Inhibitors

weak serotonin reuptake inhibitor

Other

possible monoamine oxidase inhibition

History & Culture

5-MeO-DiPT was first synthesized and tested by American chemist Alexander Shulgin, who conducted the initial human trials of the compound in 1975. Shulgin subsequently co-authored a paper with M. F. Carter detailing the synthesis and human psychopharmacology of both 5-MeO-DiPT and its parent compound diisopropyltryptamine (DiPT), which was published in 1980. A more comprehensive summary of the synthesis procedure and extensive reports of human use later appeared in Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved). The compound first appeared as a novel designer drug in 1999, emerging in recreational drug markets where it gained the street name "Foxy" or "Foxy Methoxy." It has been used recreationally as a party drug and is noted for its reported aphrodisiac and tactile-enhancing properties. The substance has seen particular use in chemsex contexts, with notable prevalence among gay men and transgender women seeking its reputed sexual enhancement effects.

Toxicity

PsychonautWiki

The long-term health effects of recreational 5-MeO-DiPT use do not seem to have been studied in any scientific context, and the exact toxic dose is unknown. This is because 5-MeO-DiPT is a research chemical with very little history of human usage. The neurotoxic effects have been studied in rats. Anecdotal reports suggest that there are no negative health effects attributed to simply trying it by itself at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.

Overdose

Excessive doses have caused nausea, vomiting, agitation, decreased blood pressure, pupil dilation, increased heart rate, and hallucinations in a number of young adults. Rhabdomyolysis and renal failure occurred in one young man, and another one died 3–4 hours after an apparent rectal overdose. A 24-year-old man also died of this compound being administered into the colon.

Effect Profile

Curated + 326 Reports

Psychedelic 8.4

Strong visuals, auditory effects, body load, and headspace

Visual Intensity×3

10102.6

Headspace Depth×3

96.62.3

Auditory Effects×1

10102.8

Body Load / Somatic Effects×1

10105.5

Catalog Erowid BlueLight

Empathogen 8.3

Strong euphoria, stimulation, and sensory enhancement with moderate empathy

Empathy / Social Openness×3

65.31.5

Euphoria / Mood Elevation×2

107.34.5

Stimulation×1

107.05.2

Sensory Enhancement×1

10103.9

Catalog Erowid BlueLight

Stimulant 5.9

Strong anxiety/jitters and euphoria with moderate stimulation, mild focus

Stimulation / Energy×3

78.0

Euphoria / Mood Lift×2

95.7

Focus / Productivity×2

45.8

Anxiety / Jitters×1

108.9

Catalog Erowid

Based on reports from:

TiHKAL TiHKAL #37: 5-MeO-DIPT Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 5-MeO-DiPT

Duration Timeline

Bluelight

Onset Comeup Peak Offset After Effects

Oral

19-40 minutes

30 minutes - 1.0 hours

1-2 hours

2-4 hours

2-6 hours

Total: 6-12 hours

Insufflated

4-19 minutes

15-30 minutes

45 minutes - 1.5 hours

1-3 hours

2-4 hours

Total: 4-8 hours

Smoked

1-4 minutes

4-10 minutes

30 minutes - 1.5 hours

1-2 hours

2-6 hours

Total: 4-8 hours

Empirical Duration

Erowid Reports

Onset Come Up Peak Offset

Oral (39 reports)

Community Effects

TripSit

Positive

euphoria body high music enhancement

Negative

nausea body load tachycardia

Tolerance & Pharmacokinetics

drugs.wiki

Tolerance Decay

Full tolerance 1h Half tolerance 10d Baseline ~14d

Cross-Tolerances

LSD

80% ●○○

Psilocybin

85% ●○○

Psilocin

85% ●○○

Mescaline

65% ●○○

DMT

85% ●○○

5-MeO-DMT

85% ●○○

2C-B

65% ●○○

2C-E

65% ●○○

Experience Report Analysis

Erowid BlueLight

267 Reports

1998–2023 Date Range

19 With Age Data

32 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid + Bluelight

Effects aggregated from 317 experience reports (267 Erowid + 59 Bluelight)

317 Reports

156 Effects Detected

64 Positive

61 Adverse

31 Neutral

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 64

Color Enhancement 47.3% 85%

Stimulation 44.1% 82%

Music Enhancement 43.2% 85%

Euphoria 38.8% 86%

Tactile Enhancement 36.9% 86%

Libido Enhancement 28.0% 86%

Body High 27.4% 86%

Focus Enhancement 24.9% 80%

Patterning 24.0% 84%

Joy 24.0% 86%

Empathy 23.4% 78%

Surface Breathing 20.0% 82%

Visual Trails 20.0% 84%

Introspection 18.0% 82%

Awe 16.0% 84%

Sociability Enhancement 16.0% 84%

Orgasm Enhancement 14.0% 86%

Insight 14.0% 76%

Melting/flowing 14.0% 83%

Contentment 12.0% 82%

Adverse Effects 61

Body Load 50.0% 86%

Nausea 37.9% 81%

Anxiety 36.3% 84%

Tremor 32.0% 82%

Muscle Tension 27.8% 88%

Confusion 25.6% 84%

Focus Suppression 18.0% 77%

Depersonalization 16.0% 81%

Fear 16.0% 86%

Insomnia 16.0% 77%

Thought Loops 14.0% 79%

Restlessness 14.0% 82%

Thought Disorganization 14.0% 80%

Heaviness 10.0% 82%

Stomach Cramps 10.0% 76%

Thought Acceleration 10.0% 81%

Vomiting 10.0% 82%

Vibrating 10.0% 84%

Jaw Clenching 9.8% 81%

Headache 8.5% 76%

Dose-Response Correlation

How effect frequency changes across dose levels

Oral

View data table

Effect	Light (n=33)	Common (n=62)	Strong (n=24)	Heavy (n=38)
Visual Distortions	63.6%	80.6%	75.0%	89.5%
Music Enhancement	45.5%	69.4%	62.5%	26.3%
Euphoria	57.6%	37.1%	41.7%	34.2%
Anxiety	39.4%	30.6%	54.2%	55.3%
Stimulation	54.5%	48.4%	41.7%	39.5%
Empathy	30.3%	24.2%	54.2%	21.1%
Color Enhancement	51.5%	48.4%	50.0%	44.7%
Auditory Effects	51.5%	35.5%	50.0%	31.6%
Tactile Enhancement	39.4%	40.3%	50.0%	31.6%
Muscle Tension	48.5%	32.3%	37.5%	18.4%
Nausea	33.3%	32.3%	41.7%	39.5%
Focus Enhancement	30.3%	40.3%	12.5%	23.7%
Confusion	18.2%	29.0%	33.3%	39.5%
Hospital	9.1%	8.1%	12.5%	31.6%
Introspection	30.3%	19.4%	25.0%	7.9%

Insufflated

View data table

Effect	Threshold (n=12)
Visual Distortions	83.3%
Stimulation	66.7%
Closed-Eye Visuals	41.7%
Muscle Tension	41.7%
Empathy	33.3%
Body High	33.3%
Tactile Enhancement	33.3%
Color Enhancement	33.3%
Music Enhancement	33.3%
Focus Enhancement	33.3%
Nausea	33.3%
Sedation	25.0%
Confusion	25.0%
Introspection	25.0%
Time Distortion	25.0%

Subjective Effect Ontology

Experience Reports

Structured effect tags extracted from 326 Erowid & Bluelight experience reports using a controlled vocabulary of 220+ canonical effects across 15 domains.

Auditory

music enhancement 137 42.7%

Emotional

euphoria 123 38.9% anxiety 115 36.0%

Gastrointestinal

nausea 120 38.0%

Motor

stimulation 140 43.8%

Tactile

tactile enhancement 117 36.5%

Visual

visual distortions 205 63.3% color enhancement 150 47.2%

8 unique effects extracted · Derived from Erowid & Bluelight reports

Dose–Effect Mapping

Experience Reports

How reported effects shift across dose tiers, based on 267 experience reports.

Insufflated dose range: 3.0–13.0 mg (median 10.0 mg)

Effect	Threshold (n=12)
visual distortions	83%
stimulation	67%
closed-eye visuals	42%
muscle tension	42%
empathy	33%
body high	33%
tactile enhancement	33%
color enhancement	33%
music enhancement	33%
focus enhancement	33%
nausea	33%
sedation	25%
confusion	25%
introspection	25%
time distortion	25%
euphoria	25%
jaw clenching	17%
open-eye visuals	17%
anxiety	17%

Oral dose range: 10.0–18.0 mg (median 12.0 mg)

Effect	Light (n=33)	Common (n=62)	Strong (n=24)	Heavy (n=38)
visual distortions	64%	81%	75%	90%	↑
music enhancement	46%	69%	62%	26%	↓
euphoria	58%	37%	42%	34%	↓
anxiety	39%	31%	54%	55%	↑
stimulation	54%	48%	42%	40%	↓
empathy	30%	24%	54%	21%	↓
color enhancement	52%	48%	50%	45%	→
auditory effects	52%	36%	50%	32%	↓
tactile enhancement	39%	40%	50%	32%	↓
muscle tension	48%	32%	38%	18%	↓
nausea	33%	32%	42%	40%	↑
focus enhancement	30%	40%	12%	24%	↓
confusion	18%	29%	33%	40%	↑
hospital	9%	8%	12%	32%	↑
introspection	30%	19%	25%	8%	↓
body high	30%	24%	29%	29%	→
sedation	27%	18%	29%	24%	→
closed-eye visuals	15%	21%	25%	5%	↓
headache	12%	6%	21%	—	↑
dissociation	15%	19%	12%	16%	→

Showing top 20 of 32 effects

Risk Escalation

Sentiment Analysis

Average frequency of positive vs adverse effects across dose tiers (Oral)

Light n=33

10 positive 37.6% 9 adverse 21.9%

Common n=62

10 positive 35.5% 11 adverse 16.0%

Strong n=24

9 positive 40.8% 9 adverse 26.4%

Heavy n=38

10 positive 26.6% 11 adverse 20.8%

View effect breakdown

Adverse Effects

Effect	Light (n=33)	Common (n=62)	Strong (n=24)	Heavy (n=38)	Change
Anxiety	39%	31%	54%	55%	+40%
Muscle Tension	48%	32%	38%	18%	-62%
Nausea	33%	32%	42%	40%	+18%
Confusion	18%	29%	33%	40%	+117%
Headache	12%	6%	21%	—	+71%
Memory Suppression	—	6%	—	18%	+183%
Psychosis	—	—	12%	18%	+47%
Sweating	6%	5%	17%	10%	+72%
Jaw Clenching	15%	14%	—	—	-4%
Motor Impairment	—	6%	12%	5%	-18%
Increased Heart Rate	12%	6%	8%	10%	-13%
Pupil Dilation	12%	6%	—	8%	-34%
Seizure	—	—	—	5%	0%

Positive Effects

Effect	Light (n=33)	Common (n=62)	Strong (n=24)	Heavy (n=38)	Change
Music Enhancement	46%	69%	62%	26%	-42%
Euphoria	58%	37%	42%	34%	-40%
Stimulation	54%	48%	42%	40%	-27%
Empathy	30%	24%	54%	21%	-30%
Color Enhancement	52%	48%	50%	45%	-13%
Tactile Enhancement	39%	40%	50%	32%	-19%
Focus Enhancement	30%	40%	12%	24%	-21%
Introspection	30%	19%	25%	8%	-73%
Body High	30%	24%	29%	29%	-4%
Creativity Enhancement	6%	3%	—	8%	+29%

Dosage Distribution

Dose distribution from experience reports

Oral

Median: 12.0 mg IQR: 10.0–18.0 mg n=151

Insufflated

Median: 10.0 mg IQR: 3.0–13.0 mg n=13

Real-World Dose Distribution

62K Doses

From 361 individual dose entries

Oral (n=265)

Median: 12.0mg 25th: 9.0mg 75th: 16.0mg 90th: 24.6mg

mg/kg median: 0.17 mg/kg 75th: 0.266

Insufflated (n=39)

Median: 7.0mg 25th: 3.0mg 75th: 10.0mg 90th: 13.4mg

mg/kg median: 0.101 mg/kg 75th: 0.17

Smoked (n=9)

Median: 8.0mg 25th: 5.0mg 75th: 11.0mg 90th: 21.0mg

mg/kg median: 0.143 mg/kg 75th: 0.23

Intravenous (n=5)

Median: 5.0mg 25th: 5.0mg 75th: 5.0mg 90th: 5.0mg

mg/kg median: 0.067 mg/kg 75th: 0.079

Intramuscular (n=6)

Median: 2.0mg 25th: 2.0mg 75th: 3.5mg 90th: 4.0mg

mg/kg median: 0.026 mg/kg 75th: 0.046

Common Combinations

Most co-occurring substances in experience reports

Form / Preparation

Most common forms and preparations reported

Body-Weight Dosing

Dose relative to body weight from reports with weight data

Oral

Median: 0.176 mg/kg IQR: 0.127–0.261 mg/kg n=140

Insufflated

Median: 0.092 mg/kg IQR: 0.051–0.169 mg/kg n=13

Redose Patterns

Redosing behavior across 210 reports

18.1% Redosed

1.3 Avg Doses

31m Median Interval

Read full reports on Erowid →

Legal Status

Country	Status	Notes
Brazil	Illegal	Listed on Portaria SVS/MS nº 344. Possession, production, and sale are prohibited under national health surveillance regulations.
Canada	Unscheduled	Not listed in Canada's schedules of controlled substances under the Controlled Drugs and Substances Act (CDSA) as of available documentation.
China	Category I psychotropic substance	Controlled substance as of October 2015. Sale, purchase, import, export, and manufacture are prohibited under SFDA regulations.
Denmark	Illegal	Controlled since February 20, 2004. Possession outside of licensed research and medical contexts is prohibited.
Finland	Illegal	Banned in December 2014 under government regulations that prohibited over 100 psychoactive substances.
Germany	Anlage I BtMG	Listed in Schedule I of the Betäubungsmittelgesetz (Narcotics Act) since October 10, 2000. Manufacturing, possession, import, export, purchase, sale, and dispensing without license are prohibited.
Greece	Controlled substance	Designated a controlled substance on February 18, 2003 under national drug control legislation.
Japan	Controlled substance	Prohibited since April 17, 2005 under Japanese drug control laws.
Latvia	Illegal	Classified as a controlled substance under Latvian national drug legislation.
New Zealand	Class C (analogue)	May be treated as a Class C controlled drug under analogue provisions due to structural similarity to DMT.
Singapore	Class A	Controlled as a Class A substance since early 2006. Trafficking penalties include imprisonment ranging from 5 to 20 years and caning.
Sweden	Illegal (health hazard)	Classified as a 'health hazard' under Lagen om förbud mot vissa hälsofarliga varor since October 1, 2004 via regulation SFS 2004:696. Sale and possession are prohibited.
Switzerland	Controlled (Verzeichnis E)	Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics regulations.
United Kingdom	Class A	Controlled under the Misuse of Drugs Act 1971 as an ether of 5-HO-DiPT, which falls under the tryptamine catch-all clause. Class A substances carry the most severe penalties.
United States	Schedule I	Emergency scheduled by the DEA on April 4, 2003, then formally placed into Schedule I of the Controlled Substances Act on September 29, 2004. Manufacturing, possession, buying, selling, and distribution require a DEA license.

References

Data Sources

Cited References

← Back to 5-MeO-DiPT